SL Science

SL Science is a South Korean biotechnology holding company focused on the development of innovative gene and cell therapies through its primary operating subsidiary, SL Bigen. The company specializes in two core technology platforms: high-expression DNA vaccines and long-acting cytokine fusion proteins designed to enhance and modulate immune responses. Its lead clinical candidate, SL-T10, is a therapeutic DNA vaccine currently in Phase 2 trials for the treatment of HPV-associated cervical intraepithelial neoplasia. Additionally, the company is advancing SL-B10, a long-acting Interleukin-7 (IL-7) therapy aimed at treating lymphopenia and various solid tumors. SL Science operates as the life sciences arm of the SL Corporation group, leveraging strategic partnerships to expand its pipeline in oncology and immunology.